Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal.

Published in: The British journal of dermatology (2018)

Warren et al. conclude that the 52-week risk-benefit profile of subcutaneous methotrexate is favourable in patients with psoriasis.

Keyphrases